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When injury occurs, it implies that attack has overcome defence. Tubulointerstitial injury plays 
important roles in acute kidney injury (AKI) and chronic kidney disease (CKD), and is the common 
pathway leading to end-stage renal disease, but how the renal tubulointerstitium defends against 
attack is poorly understood. Emerging evidence suggests that collecting ducts (CDs), which modify 
urine from nephrons and drain into ureter, could be key defenders protecting tubulointerstitium 
from injury; furthermore, the canonical renal vitamin A signalling physiologically confined to CDs 
could be a key regulator of this protective machinery. This hypothesis can be tested by in-vitro, in-
vivo and clinical studies, particularly by repressing or boosting key molecular regulators in CDs, to 
observe the resulting phenotypes in models of AKI and CKD. Further investigation of this hypothesis 
could lead to new strategies for diagnosis, prevention and treatment of AKI and CKD. 
 
Background 
Kidneys and renal medicine are often regarded as the “victims of their own success”. Kidneys have 
remarkable functional reserves and renal medicine is among the most successful in replacement 
therapies when kidneys do fail [1]. Patients with end-stage renal disease (ESRD) on dialysis or kidney 
transplantation can maintain life, but these therapies are costly, donor organs are in short supply and 
mortality rates are high—young patients (20-49 years old) on these therapies are 16-25 times more 
likely to die in one year than the age-matched general population [2]. Rates of acute kidney injury 
(AKI) and chronic kidney disease (CKD) are increasing worldwide and the intercalated AKI-CKD 
syndrome continues to cause more ESRD and mortality [3,4]. The nephrology community has been 
promoting the “0by25” initiative for AKI (zero preventable deaths by 2025)” [5], but few effective 
strategies exist to prevent AKI, CKD and the progression to ESRD. 
Why are AKI and CKD such intractable problems? To answer this question, advice from past 
presidents of the American Society of Nephrology is worth noting: we must “emphasise innovation” 
[6] and “build new paths to kidney health” [7]. 
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“Modern medicine can learn from traditional practices”, concluded GP-TCM, European Union’s first 
ever Coordination Action on modernisation of traditional Chinese medicine (TCM) under its Seventh 
Framework Programme [8]. As a nephrologist and the principal investigator of the consortium, I think 
that innovation in modern nephrology could be catalysed by the wisdom from Yellow Emperor’s 
Inner Canon, a TCM classic inscribed in the Memory of the World Register, United Nations 
Educational, Scientific and Cultural Organization [9], which says: “When there is sufficient protective 
qi inside, pathogenic factors have no way to hurt the body; when pathogenic factors cause damage, 
the internal qi must be deficient.” Herein, qi means the internal mechanisms of the body that defend 
against attack.  
However, in nephrology most of the past work on AKI and CKD focused on how attacks damage, with 
relatively less consideration of the defending mechanisms in the kidney. In particular, although 
tubulointerstitial injury plays important roles in AKI [4] and progressive tubulointerstitial damage is 
the common pathway to ESRD [10], the protective mechanisms by which the renal tubulointerstitium 
defends against a variety of injurious stimuli is relatively less known. 
 
Hypothesis 
Inspired by recent findings of my laboratory [11-14], I hypothesise that collecting ducts (CDs) are key 
to the defence of the tubulointerstitium and are regulated by the canonical vitamin A signalling 
mediated by retinoic acid (RA) and retinoic acid receptors (RARs). 
 
Evidence supporting a key defence role for CDs 
Studies on AKI and CKD have traditionally focused on glomeruli, proximal tubules and the 
vasculature, leaving distal tubules and CDs largely neglected. In particular, CDs are the only tubules 




Importantly, in addition to principal cells that regulate water homeostasis and intercalated cells that 
regulate acid-base balance, CDs are equipped with specialised pro-repair and pro-regenerative 
mesenchymal stem cells [15] and defence molecules, e.g. antimicrobial b-defensins [16] and anti-
fibrotic microRNAs [17]. Expression of many genes crucial for renal development, e.g. Pax2, Wnt4 
and Wnt7b, is also confined to CDs in the adult kidney [18]. Could these genes adapt to protective 
roles? Furthermore, CDs are equipped with RA/RAR physiological signalling [11,12]. A defence role 
for RA/RARs is highlighted by the susceptibility to pyelonephritis and urolithiasis in rats fed a vitamin 
A-deficient diet [19]. Since RA is effective in treating many models of AKI and CKD [20-22], 
endogenous RA/RARs in CDs may have been evolutionarily selected for protection against injury. To 
pinpoint roles for RA/RARs in CD cells, my laboratory has catalogued RA/RAR-dependent mRNAs in 
CD cells at a pan-genomic level, which support a critical role for the RA/RAR signalling in maintaining 
gene expression implicated in defence against infection (Ppbp, Lcn2, Upk3b), inflammation (Ppbp, 
Cpm, Muc20) and fibrosis (Bmp7) [11]. Thus, RA/RAR signalling in CDs, including its target genes, may 
serve as an important regulator for defence against tubulointerstitial damage. 
Emerging evidence suggests that renal RA/RAR signalling plays important roles in AKI and CKD. In 
resolving AKI, CDs are relatively spared and renal RA/RAR activity is increased [21]. Conversely, in 
progressive CKD induced by unilateral ureteral obstruction, renal RAR expression decreases [22], and 
in mice with diabetic nephropathy there is a kidney-specific impairment of RA/RAR signalling [23]. 
Work in my laboratory has shown that endogenous RA/RAR activity is conserved in both mouse and 
human CD cells, including cortical and medullary CD cells and CD-derived mesenchymal stem cells (Xu 
Q et al, unpublished data) [13]. Furthermore, albumin specifically and dose-dependently represses 
RA/RAR activity in CD cells, suggesting that albuminuria, the leading risk factor for CKD progression, 
may contribute to CKD progression by repressing RA/RAR activity in CDs (Xu Q et al, unpublished 
data) [13]. In addition, angiotensin II, aldosterone, endotoxin and high glucose, which all contribute 
to CKD, dose-dependently repress RA/RAR signalling in CD cells, while gentamicin and aristolochic 
acid, which are known to induce AKI, increase signalling in cultured CD cells (Xu Q et al, unpublished 
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data) [13]. Thus, RA/RAR signalling in CD cells appears to be a convergence point of regulation by AKI 
and CKD risk factors and may be a novel target for AKI and CKD prevention and treatment. 
 
Central questions and key experiments proposed to test the hypothesis 
CDs are structurally and functionally important for the kidney. They serve to drain urine from 
nephrons to ureters and plays fundamental roles in maintaining fluid and electrolyte homeostasis. 
Thus, any experiments proposed to test the hypothesised new protective roles for CDs must first 
ensure that the classical structural and functional roles for CDs are preserved. To determine the 
protective roles for CDs, it is important to identify potential protective effectors in CDs and test their 
functions and such experiments must be designed carefully at the molecular, subcellular and cellular 
levels. To begin with, at the molecular level, I propose to test the roles for Pax2, Wnt4, Wnt7b and 
the RA/RAR signalling in CDs as protective effectors in AKI and CKD models [11-14,18], while other 
candidate genes and signals are to be identified. I would like to propose the following key questions: 
How do CD cells maintain resilience? How do CDs protect other tubulointerstitial cells? What are the 
roles for CD-specific gene expression, RA/RAR signalling and CD-derived microvesicles and 
mesenchymal stem cells in renal tubulointerstitial defence? How do these mechanisms interact? 
How is CD defence regulated in AKI and CKD? Is failure of CD defence a cause of more severe AKI, 
chronicity and CKD progression? Do CDs secrete defence molecules into the urine and express 
defence biomarkers in biopsied renal tissue? Can these biomarkers predict prognosis and guide 
treatment? Finally, can novel therapies be devised to prevent AKI, AKI transition to CKD, and CKD 
progression to ESRD by modulating CD defence? 
To test whether and how CD cells, including principal cells, intercalated cells and CD-derived 
mesenchymal stem cells, protect other renal cells, co-culture of these CD-derived cells and other cells 
in the presence of various types of stress and nephrotoxins could be a useful in-vitro model. 
Conditional, CD-specific deletion, silencing or overexpression of Pax2, Wnt4, Wnt7b and other genes 
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of interest in animal models will establish in-vivo proof of concept of the roles of these genes in the 
CDs in AKI and CKD. To determine whether RA/RAR signalling in CDs plays an important role in AKI 
and CKD, spatiotemporal changes of renal RA/RAR activities in different AKI and CKD models could be 
visualised and quantified in RA/RAR activity reporter mice [12,24]; and as illustrated in Fig. 1, AKI and 
CKD models could be induced in transgenic mice in which RA/RAR signalling in CDs is conditionally 
repressed or boosted. 
To examine the specificity of any proposed protective role for CDs, it is important to compare roles 
for specific genes and signals in CDs versus other tubules. For example, repressing microRNA 
biogenesis in CDs but not in proximal tubules leads to renal fibrosis, supporting a specific role for CDs 
in supplying anti-fibrotic microRNAs [17,25]. In contrast, deleting the TGF-b type II receptor in either 
CDs or proximal tubules leads to similar pro-fibrotic phenotypes, suggesting that the anti-fibrotic 
effect of the TGF-b type II receptor in CDs is not unique [26,27]. 
Many genes (e.g. Pax2, Wnt4 and Wnt7b) and signals (e.g. the RA/RAR signalling) in CDs that are 
potential protectors are indispensable in renal development. Thus, silencing genes or repressing 
RA/RAR signalling non-conditionally may lead to malformation of the foetal kidney and embryonic 
lethality thus preventing further studies on their roles in adult AKI and CKD. To test my hypothesis, 
reliable conditional gene knockout or transgenes to facilitate conditional gene expression changes 
specifically in adult renal CDs will be needed. However, CD-specific gene modification remains a 
challenge. Promoters of Hoxb7, Aqp2 and Atp6v1b1 are most commonly used to selectively regulate 
gene expression in CDs, but the promoter activity of Hoxb7 is not strictly confined to CDs [28]; Aqp2 
is only expressed in CD principal cells and CD-derived mesenchymal stem cells [15]; while Atp6v1b1 is 
only expressed in CD intercalated cells and some hybrid cells [29]. Thus, it remains a challenge to find 
pan-CD cell-specific promoters. Based on single-cell transcriptomic analysis of different mouse CD 
cells [29], to target all major CD cells during adulthood, the best approaches may still be inducible 




Clinically and in animal models, whether CD-derived urinary microvesicles in AKI and CKD could 
report activation or failure of the defence capacity and thus predict disease prognosis is worthy of 
investigation. CDs and other tubules micro-dissected from biopsies of patients or animal models of 
AKI and CKD could be subjected to in-depth analysis to guide discovery of novel mediators of CD 
defence. Finally, retinoids and non-retinoid therapies mobilising protective mechanisms in CDs could 
be explored for the prevention and treatment of AKI and CKD. 
Conclusions 
A new role for CDs in protecting the renal tubulointerstitium is proposed, supplementing their role in 
controlling urinary fluid and electrolyte composition. Further investigation of this hypothesis could 
lead to a paradigm shift in understanding kidney health and may lead to new strategies for diagnosis, 
prevention and treatment of AKI and CKD. Although this paper focuses on the kidney, CDs are also 
important in protecting the heart [30]. Given that non-immune defence mechanisms are generally 
overlooked in modern medicine, it is hoped that this special article will inspire not only 
nephrologists, but also other physicians and medical scientists alike, to perceive health and disease in 
light of the balance and imbalance between attack and defence. 
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Fig. 1. A hypothesised protective role for the canonical vitamin A signalling in CDs and proposed 
points for experimental intervention in order to test the hypothesis [11,12, 20]. Vitamin A (Rol) is 
metabolised to RA via two oxidation steps. While the first step is reversibly catalysed by alcohol 
dehydrogenases (Adhs) 1-4 and dehydrogenase/reductase (SDR family) member 3 (Dhrs3), 
respectively, the second step converting retinaldehyde (Ral) into RA is catalysed by aldehyde 
dehydrogenase family 1 subfamily a1-3 (Aldh1a1, a2 and a3) and is irreversible. RA binds RARs in 
heterodimers of retinoid X receptors (RXR) and RAR to regulate gene expression. In RAR/RXR 
heterodimers, RXRs are silent. Thus RA-activated RAR/RXR signalling is also simplified as RA/RAR 
signalling. By tetracycline-inducible, CD-specific promoter-driven overexpression of a dominant 
negative mutant RAR (to antagonise RARs) and an RA-metabolising enzyme, e.g. Cyp26a1 (to 
eliminate RA), the RA/RAR signalling in CDs can be repressed on demand¾this approach will be 
suitable to examine roles for the RA/RAR signalling in CDs when it is relatively high; by conditional, 
CD-specific overexpression of Aldhs (to increase RA synthesis) or deletion of Dhrs3 (to increase RA 
precursors), the RA/RAR activity in CDs can be boosted¾this approach will be suitable to examine 
roles for the RA/RAR signalling in CDs when it is repressed. Proposed points of intervention are 
highlighted by red fonts. 
